Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a crossover study to assess the systemic pharmacokinetics of fluticasone propionate
(FP) and salmeterol (SAL). Study medication will be administered as fixed dose combinations
(250 µg FP and 50 µg SAL) from the Advair® Diskus®, Seretide™ Accuhaler™ and CRC749 inhalers.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Inc.
Collaborator:
Mylan Pharmaceuticals
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate